NASDAQ: OBSVObseva Sa Stock
$0.18-0.03 (-14.29%)
Updated Dec 2, 2022
OBSV Price
$0.18
Fair Value Price
$0.38
Market Cap
$15.40M
52 Week Low
$0.13
52 Week High
$2.45
P/E
-0.24x
P/B
-7.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$63.83M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-26.77
Operating Cash Flow
-$56M
Beta
0.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OBSV Overview
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OBSV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OBSV ($0.18) is undervalued by 51.65% relative to our estimate of its Fair Value price of $0.38 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
OBSV ($0.18) is significantly undervalued by 51.65% relative to our estimate of its Fair Value price of $0.38 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
OBSV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OBSV due diligence checks available for Premium users.
Be the first to know about important OBSV news, forecast changes, insider trades & much more!
OBSV News
Valuation
OBSV fair value
Fair Value of OBSV stock based on Discounted Cash Flow (DCF)
Price
$0.18
Fair Value
$0.38
Undervalued by
52.71%
OBSV ($0.18) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OBSV ($0.18) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OBSV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OBSV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.24x
Industry
13.84x
Market
21.89x
OBSV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-7.32x
Industry
5.06x
OBSV's financial health
Profit margin
Revenue
$0.0
Net Income
-$32.8M
Profit Margin
0%
OBSV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$54.2M
Liabilities
$56.3M
Debt to equity
-26.77
OBSV's short-term assets ($48.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OBSV's short-term assets ($48.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OBSV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OBSV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.7M
Investing
-$11.0k
Financing
-$1.2M
OBSV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OBSV vs Biotech Stocks
Obseva Sa Stock FAQ
©2022 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.